Pierre Fabre étend sa collaboration avec Puma Biotechnology
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Fight against cancer : our therapeutic responses | Pierre Fabre
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Fight against cancer : our therapeutic responses | Pierre Fabre
Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotech Expands Pierre Fabre License to Add Countries
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Accord entre Pierre Fabre et Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Puma regains China rights to Nerlynx and amends deal with Fabre
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
